Hypophosphatasia Explained: Low ALP, ALPL Mutation, Osteomalacia, Fractures and Asfotase Alfa

What Is Hypophosphatasia?

Opening

Alkaline phosphatase is often taught as a laboratory value that becomes elevated in bone disease.

But one important metabolic bone disorder teaches the opposite lesson:

Hypophosphatasia, or HPP, is a rare inherited disorder caused by pathogenic variants affecting:

the gene encoding tissue-nonspecific alkaline phosphatase.

Reduced tissue-nonspecific alkaline phosphatase activity interferes with normal mineralization of bone and teeth.

The clinical spectrum is extremely broad.

Severe disease may present before or shortly after birth.

Milder disease may remain unrecognized until adulthood, when a patient presents with:

• recurrent metatarsal stress fractures;
• femoral pseudofractures;
• poor fracture healing;
• bone or muscle pain;
• premature tooth loss;
• chondrocalcinosis;
• or an apparent diagnosis of osteoporosis.

GeneReviews describes adult HPP particularly in association with osteomalacia, lower-extremity stress fractures and pseudofractures, dental disease, musculoskeletal pain and weakness. (NCBI)

The central diagnostic sequence is:

First Important Concept — The Name Is Misleading

Create a callout:

The name refers to:

not simply low serum phosphate.

The distinction is:

Hypophosphatasia

with:

See hypophosphatemia.

or:

X-linked hypophosphatemia

These are different disorders.

• Hypophosphatemia
• X-Linked Hypophosphatemia

Why Alkaline Phosphatase Matters

Alkaline phosphatase exists in several tissue-associated forms.

The major enzyme involved in HPP is:

abbreviated:

It is expressed particularly in:

• bone;
• liver;
• kidney.

In bone, TNSALP is produced prominently by osteoblast-lineage cells and contributes to normal mineralization.

Its critical role includes controlling extracellular concentrations of:

PPi inhibits hydroxyapatite crystal formation.

Normally:

This reduces the mineralization inhibitor and permits normal hydroxyapatite formation.

ALPL and TNSALP

This is the core physiology of the article.

How Hypophosphatasia Causes Defective Mineralization

Bone formation is not complete simply because osteoblasts produce osteoid.

That osteoid must subsequently become mineralized.

Hydroxyapatite crystals must form and propagate within the matrix.

In HPP, excess extracellular PPi acts as:

Therefore:

but:

In children this may produce:

In adults:

Osteomalacia Explained

PLP, PEA and Pyrophosphate

Other Tnsalp Substrates

Reduced TNSALP activity also leads to accumulation of substrates including:

and:

These biochemical abnormalities can support the diagnosis.

Another relevant substrate is:

but PPi testing is generally less routinely accessible.

PLP And Vitamin B6

PLP is the major circulating phosphorylated form of vitamin B6.

TNSALP participates in dephosphorylation of extracellular PLP.

When TNSALP activity is deficient:

Therefore elevated PLP can provide supportive biochemical evidence of HPP.

Important:

Also recognize that vitamin B6 supplementation can affect PLP interpretation.

Why Severe HPP Can Cause Vitamin B6-Responsive Seizures

Although circulating PLP may be elevated, phosphorylated PLP does not freely cross cell membranes.

TNSALP normally helps generate forms capable of supporting intracellular vitamin B6 metabolism.

In severe infantile HPP, disturbed vitamin-B6 metabolism in the central nervous system can contribute to:

This is a marker of severe disease.

Genetics and Inheritance

HPP results from pathogenic variants in:

Clinical severity and inheritance are variable.

Severe forms are commonly associated with:

and typically follow:

Milder disease may occur with:

• biallelic variants;
• or a single heterozygous pathogenic variant.

Some heterozygous variants can produce disease through a dominant-negative effect.

Therefore HPP may demonstrate:

or:

inheritance depending on the variant and phenotype.

GeneReviews emphasizes the broad phenotypic variability, including substantial variability within families. (NCBI)

Clinical Spectrum of HPP

HPP is a continuous clinical spectrum rather than a collection of completely separate diseases.

Traditional clinical categories remain useful for teaching.

Include:

1. severe perinatal HPP;
2. benign prenatal/perinatal form;
3. infantile HPP;
4. severe childhood/juvenile HPP;
5. mild childhood HPP;
6. adult HPP;
7. odontohypophosphatasia.

GeneReviews currently recognizes these clinical forms while emphasizing that the phenotype represents a continuum. (NCBI)

Perinatal and Infantile HPP

Severe Perinatal HPP

Severe prenatal/perinatal disease may cause profound skeletal hypomineralization.

Potential features include:

• markedly impaired skeletal mineralization;
• shortened or bowed limbs;
• poorly mineralized bones;
• chest deformity;
• respiratory compromise.

The most serious consequence is:

because inadequate mineralization of the thoracic skeleton can impair respiratory mechanics.

Severe disease may also be associated with:

• hypercalcemia;
• vitamin-B6-dependent seizures;
• high morbidity and mortality.

(NCBI)

Infantile HPP

Infantile disease becomes clinically apparent during early infancy.

Potential features include:

• rickets;
• poor growth;
• skeletal deformity;
• hypotonia;
• respiratory problems;
• hypercalcemia;
• hypercalciuria;
• nephrocalcinosis;
• craniosynostosis;
• vitamin-B6-responsive seizures.

Important examination clue:

is very different from the usual nutritional-rickets pattern where ALP is generally elevated.

Childhood HPP

Childhood disease may include:

• premature loss of primary teeth;
• bone pain;
• fractures;
• skeletal deformity;
• short stature;
• abnormal gait;
• muscle weakness;
• impaired mobility;
• rachitic abnormalities.

One particularly characteristic dental clue is:

GeneReviews notes that premature deciduous-tooth loss often begins with the incisors. (NCBI)

Dental Manifestations

Why The Teeth Fall Out

TNSALP deficiency affects mineralized dental tissues, particularly:

Cementum contributes to attachment of the periodontal ligament to the tooth root.

Defective cementum formation can impair tooth anchoring.

Therefore:

giving the characteristic:

This is a valuable clinical clue.

Odontohypophosphatasia

Some patients predominantly show dental manifestations without obvious skeletal disease.

This phenotype is called:

Features may include:

• premature primary-tooth loss;
• severe dental caries;
• alveolar bone abnormalities.

However, some individuals initially presenting with apparently isolated dental disease may later develop additional manifestations. (NCBI)

Adult Hypophosphatasia

Adult HPP is particularly important because it can be:

or:

Adult manifestations may include:

• recurrent stress fractures;
• metatarsal fractures;
• femoral pseudofractures;
• poor fracture healing;
• bone pain;
• muscle pain;
• muscle weakness;
• reduced mobility;
• early tooth loss;
• chondrocalcinosis;
• osteoarthropathy;
• fatigue;
• reduced quality of life.

(NCBI)

Stress Fractures and Pseudofractures

Metatarsal Stress Fractures

A classic adult presentation is:

The patient may present with:

• foot pain;
• recurrent fractures;
• prolonged healing;
• fractures after relatively limited trauma.

Repeated metatarsal fractures plus persistently low ALP should strongly raise suspicion for HPP.

Femoral Pseudofractures

Adult HPP may produce:

also called:

These represent areas of incomplete fracture through poorly mineralized bone.

Thigh or hip pain may precede recognition.

GeneReviews particularly describes pseudofractures involving the lateral cortex of the femoral diaphysis. (NCBI)

Pseudofracture Versus Ordinary Fracture

A pseudofracture reflects:

rather than simply an acute traumatic break through otherwise normally mineralized bone.

It is therefore an important clue to:

Osteomalacia Explained

Chondrocalcinosis and Joint Disease

HPP can also be associated with:

and:

This is biologically related to abnormal extracellular pyrophosphate metabolism.

Therefore an adult with:

• persistently low ALP;
• fractures;
• and chondrocalcinosis;

deserves consideration of HPP.

GeneReviews includes chondrocalcinosis and osteoarthropathy among adult manifestations. (NCBI)

Persistently Low ALP

The Most Important Laboratory Clue

Display prominently:

This is the biochemical hallmark.

But the word:

is essential.

A single low result should not establish the diagnosis.

The 2024 consensus recommendations advise at least two separate ALP measurements, both low relative to appropriate age- and sex-specific reference ranges, when HPP is suspected. (Springer)

ALP Must Be Interpreted Correctly

ALP varies substantially with:

• age;
• sex;
• growth;
• laboratory method/reference interval.

Children normally have higher ALP because of active skeletal growth.

Therefore:

Bone-Specific ALP

Bone-specific ALP is not required to diagnose HPP.

The recent consensus specifically recommends:

and does not recommend bone-specific ALP measurement as the diagnostic test for HPP. (Springer)

Causes of Low ALP

Other causes must be considered.

Possible explanations for low ALP can include, depending on clinical context:

• malnutrition;
• deficiencies of relevant micronutrients;
• hypothyroidism;
• severe anemia;
• celiac disease/malabsorption;
• severe systemic illness;
• certain medications;
• antiresorptive treatment;
• laboratory/pre-analytical factors;
• other uncommon disorders.

The exact differential should be individualized rather than using low ALP as a genetic diagnosis.

Consensus guidance specifically recommends excluding alternative causes of low ALP. (Springer)

Diagnostic Approach

Diagnostic Approach

Create a major algorithm.

No

→ HPP biochemical criterion not established.

Yes

Not persistently low

→ investigate according to context.

Persistently low

• stress fractures;
• pseudofractures;
• poor fracture healing;
• bone/muscle pain;
• premature tooth loss;
• chondrocalcinosis;
• childhood rickets/deformity;
• family history.

PLP ↑?

PEA ↑?

Diagnostic Criteria — Teach Cautiously

Recent expert criteria use combinations of major and minor clinical features in individuals with persistently low ALP after alternative explanations have been excluded.

Diagnosis cannot be reduced to:

because:

• variant interpretation matters;
• heterozygous variants may have variable expression;
• biochemical and clinical phenotype matter.

Likewise:

Consensus diagnostic frameworks for adults and children have been proposed, but evidence quality remains limited and the field continues to evolve. (Springer)

PLP and PEA Testing

Supportive Biochemical Testing

When HPP is suspected, useful investigations may include:

• repeated total ALP;
• PLP;
• urinary PEA where available;
• calcium;
• phosphate;
• magnesium;
• renal function;
• PTH;
• 25-hydroxyvitamin D;
• urine calcium where clinically relevant.

Recent recommendations support assessment of broader calcium-phosphate metabolism because HPP can be associated with abnormalities such as hypercalcemia and hypercalciuria, particularly in more severe phenotypes. (Springer)

Not every listed test is abnormal in every patient.

Serum Phosphate

Important:

Again:

This should be repeated because of the confusing terminology.

Calcium

Calcium may be:

• normal;
• or elevated in severe disease.

Hypercalcemia can occur when impaired skeletal mineralization reduces incorporation of calcium into bone.

This is particularly relevant in severe infantile disease.

Hypercalcemia is not required for diagnosis.

Pth

PTH is not the primary diagnostic biomarker for HPP.

It should be interpreted as part of:

Imaging and DXA

Imaging

Imaging findings depend on:

• age;
• disease severity;
• fracture history.

Potential findings include:

• rickets;
• hypomineralization;
• fractures;
• pseudofractures;
• poorly healing stress fractures;
• skeletal deformities.

Adult imaging may reveal metatarsal stress fractures or femoral pseudofractures.

Imaging supports the phenotype but does not replace biochemical/genetic assessment.

DXA

DXA may demonstrate:

• reduced BMD;
• normal BMD;
• variable findings.

Therefore:

A patient with HPP can be incorrectly labeled as having ordinary osteoporosis if clinicians focus on DXA while ignoring persistently low ALP and the clinical history.

Memory:

HPP vs Osteoporosis

Implement as a table.

GeneReviews specifically emphasizes distinguishing adult HPP from osteoporosis because antiresorptive treatment can be inappropriate. (NCBI)

HPP vs Osteomalacia

Implement:

Memory:

HPP vs XLH

Implement briefly.

X-Linked Hypophosphatemia Explained

Why Misdiagnosis Matters

Why Osteoporosis Misdiagnosis Matters

This is one of the most important sections.

An adult with:

• fractures;
• low BMD;
• older age;

may appear to have conventional osteoporosis.

But if the patient also has:

plus:

• metatarsal stress fractures;
• femoral pseudofractures;
• poor fracture healing;
• premature tooth loss;

HPP should be considered.

The distinction matters because therapies designed to suppress bone turnover may be inappropriate in a mineralization disorder caused by deficient alkaline phosphatase activity.

Bisphosphonates

GeneReviews lists bisphosphonates among agents/circumstances to avoid in HPP. (NCBI)

Conceptually:

Bisphosphonates are pyrophosphate analogues and suppress bone turnover.

In a disorder already characterized by abnormal pyrophosphate metabolism and defective mineralization, this creates biological and clinical concern.

Denosumab

GeneReviews also lists:

among agents to avoid in HPP. (NCBI)

The HPP-specific lesson is simply:

Treatment Principles

Treatment depends on:

• age;
• phenotype;
• severity;
• fracture burden;
• mobility;
• respiratory involvement;
• dental disease;
• neurological complications;
• renal complications.

Goals may include:

• improve skeletal mineralization;
• reduce disease burden;
• support fracture healing;
• improve mobility/function;
• manage pain;
• protect dentition;
• manage complications;
• improve quality of life.

Asfotase Alfa

Asfotase Alfa

Create a major section.

is:

It is a recombinant form of tissue-nonspecific alkaline phosphatase engineered for skeletal targeting.

Conceptually:

This is targeted treatment of the underlying enzyme deficiency.

Current U.S. Indication

Be precise.

Current U.S. prescribing information states that Strensiq is indicated for:

and:

It should not be written as:

“FDA-approved for every adult with HPP.”

Adults whose disease began in childhood may fall within pediatric-onset disease even if treated as adults, but regulatory eligibility and clinical treatment decisions must follow current jurisdiction-specific prescribing information.

(FDA Access Data)

Asfotase Alfa Safety

The current U.S. label carries a boxed warning for:

The label states that anaphylaxis has occurred both early in treatment and after extended therapy, and initiation should occur under healthcare supervision with appropriate monitoring/support. (FDA Access Data)

Adult HPP And Enzyme Replacement

The following statement is too simplistic:

“Adult HPP cannot be treated with asfotase alfa.”

Adult age and age of disease onset are different concepts.

Instead teach:

Fracture and Dental Management

Fracture Management

Stress fractures and pseudofractures in HPP may heal slowly.

Management may require:

• metabolic-bone expertise;
• orthopedic assessment;
• appropriate mechanical support;
• selected surgical fixation.

GeneReviews notes that internal fixation has been suggested for difficult pseudofractures/stress fractures in adults. (NCBI)

Teriparatide

Limited adult experience and case reports describe teriparatide use for fracture healing, pain or osteomalacia in HPP.

However:

Evidence is limited.

It should not replace disease-specific therapy where that therapy is indicated.

GeneReviews describes adult experience as limited. (NCBI)

Dental Care

Dental care is an important part of management.

Goals include:

• preserve teeth;
• monitor periodontal/dental complications;
• recognize premature tooth loss;
• maintain oral function.

Children with early tooth loss may require coordinated dental and metabolic assessment.

HPP management extends beyond skeletal treatment.

Multidisciplinary Care

Depending on phenotype, management may involve:

• metabolic bone/endocrinology specialists;
• pediatrics;
• genetics;
• orthopedics;
• dentistry;
• nephrology;
• neurology;
• respiratory specialists;
• physiotherapy/rehabilitation.

Severe disease is multisystem.

Genetic Counseling

Because HPP can follow autosomal recessive or autosomal dominant inheritance patterns:

Counseling may address:

• inheritance;
• variant interpretation;
• family testing;
• recurrence risk;
• phenotypic variability.

Master Diagnostic Algorithm

ALP normal/high for age and sex

ALP low

No

→ investigate other explanations.

Yes

Metatarsal stress fractures?

Femoral pseudofractures?

Poor fracture healing?

Root-intact premature tooth loss?

Chondrocalcinosis?

Childhood rickets/deformity?

Family history?

Worked Clinical Cases

Case 1 — Low ALP and metatarsal fractures

A 48-year-old has recurrent metatarsal stress fractures and repeatedly low ALP.

Next thought

Confirm that ALP is persistently low for the appropriate reference range, exclude alternative causes, and evaluate supportive clinical/biochemical features.

Case 2 — One low ALP

A healthy adult has one mildly low ALP result without symptoms.

Wrong conclusion

“HPP confirmed.”

Correct approach

One low ALP value does not establish HPP.

Case 3 — Child with low ALP

A child has an ALP value that appears normal by an adult laboratory interval.

Problem

Children normally have higher ALP.

Lesson

A value apparently “normal” by adult standards may be abnormally low for a growing child.

Case 4 — Rickets with low ALP

Child has:

• bowed legs;
• rachitic imaging;
• low ALP.

Key clue

Think HPP rather than assuming nutritional vitamin-D deficiency.

Case 5 — Premature tooth loss

Four-year-old loses incisors prematurely with intact roots.

Key clue

Evaluate for HPP.

Case 6 — Osteoporosis misdiagnosis

A 55-year-old with low BMD and recurrent foot fractures has persistently low ALP.

Wrong approach

“DXA low → conventional osteoporosis → antiresorptive.”

Better approach

Case 7 — Femoral pseudofracture

Adult has chronic thigh pain and a lateral femoral pseudofracture.

ALP is persistently low.

Lesson

Case 8 — Chondrocalcinosis

Adult has:

• chondrocalcinosis;
• recurrent musculoskeletal pain;
• persistently low ALP.

Lesson

Abnormal PPi metabolism makes HPP an important consideration.

Case 9 — Elevated PLP

Patient has persistently low ALP and elevated PLP.

Interpretation

Elevated PLP:

but does not replace clinical/genetic assessment.

Case 10 — Low ALP from another cause

Patient has low ALP during severe malnutrition without characteristic HPP manifestations.

Lesson

Low ALP is not specific for HPP.

Case 11 — Adult with ALPL variant

Adult has persistently low ALP, fractures and an ALPL pathogenic variant.

Lesson

Interpret:

Case 12 — Adult seeking asfotase alfa

An adult newly diagnosed with HPP asks whether all adults receive enzyme replacement.

Answer

Treatment depends on phenotype, severity, age of onset, regulatory indication and specialist assessment.

Common Mistakes

Mistake 1

Hypophosphatasia means low phosphate.

Wrong.

Mistake 2

One low ALP diagnoses HPP.

Wrong.

Mistake 3

Any ALP below an adult reference interval diagnoses HPP.

Wrong.

Mistake 4

Adult ALP reference ranges can be applied to children.

Wrong.

Mistake 5

Bone-specific ALP is required to diagnose HPP.

Wrong.

Mistake 6

Low ALP has no differential diagnosis.

Wrong.

Mistake 7

All patients with HPP have fractures.

Wrong.

Mistake 8

All patients with HPP have low BMD.

Wrong.

Mistake 9

DXA diagnoses HPP.

Wrong.

Mistake 10

HPP and osteoporosis are the same disorder.

Wrong.

Mistake 11

HPP and hypophosphatemia are the same disorder.

Wrong.

Mistake 12

HPP and XLH are the same disorder.

Wrong.

Mistake 13

PLP alone proves HPP.

Wrong.

Mistake 14

A normal serum phosphate excludes HPP.

Wrong.

Mistake 15

Premature tooth loss is irrelevant to bone diagnosis.

Wrong.

Mistake 16

Every adult with low BMD should automatically receive a bisphosphonate.

Wrong.

Mistake 17

Antiresorptive therapy is automatically appropriate in established HPP.

Wrong.

Mistake 18

All HPP follows autosomal recessive inheritance.

Wrong.

Mistake 19

Asfotase alfa is FDA-approved for every adult with HPP.

Wrong. (FDA Access Data)

Mistake 20

HPP is only a childhood disease.

Wrong.

Hypophosphatasia in One Minute

Diagnostic clue:

Then ask:

Look for:

Stress fractures

Pseudofractures

Poor healing

Premature root-intact tooth loss

Chondrocalcinosis

Treatment principle:

Targeted therapy:

Final memory:

Frequently Asked Questions

Key Take-Home Messages

Hypophosphatasia is a disorder of:

caused by deficient:

The fundamental pathway is:

The major biochemical clue is:

but:

First establish that ALP is genuinely low for:

Then:

Adult HPP deserves particular attention because it may masquerade as:

A history of:

• recurrent metatarsal fractures;
• femoral pseudofractures;
• poor fracture healing;
• premature tooth loss;
• chondrocalcinosis;

combined with persistently low ALP should raise suspicion.

This matters because:

Asfotase alfa provides targeted enzyme replacement for appropriate HPP populations, while conventional antiresorptive osteoporosis treatment should not be applied reflexively to established HPP. (NCBI)

Final memory:

and: